The DOI matches its Crossref record; 226 of the 226 references it cites were found in a registry or an index.
The fate of chemoresistance in triple negative breast cancer (TNBC)
Open accessAbstract
BACKGROUND: Treatment options for women presenting with triple negative breast cancer (TNBC) are limited due to the lack of a therapeutic target and as a result, are managed with standard chemotherapy such as paclitaxel (Taxol®). Following chemotherapy, the ideal tumour response is apoptotic cell death. Post-chemotherapy, cells can maintain viability by undergoing viable cellular responses such as cellular senescence, generating secretomes which can directly enhance the malignant phenotype. SCOPE OF REVIEW: How tumour cells retain viability in response to chemotherapeutic engagement is discussed. In addition we discuss the implications of this retained tumour cell viability in the context of the development of recurrent and metastatic TNBC disease. Current adjuvant and neo-adjuvant treatments available and the novel potential therapies that are being researched are also reviewed. MAJOR CONCLUSIONS: Cellular senescence and cytoprotective autophagy are potential mechanisms of chemoresistance in TNBC. These two non-apoptotic outcomes in response to chemotherapy are inextricably linked and are neglected outcomes of investigation in the chemotherapeutic arena. Cellular fate assessments may therefore have the potential to predict TNBC patient outcome. GENERAL SIGNIFICANCE: Focusing on the fact that cancer cells can bypass the desired cellular apoptotic response to chemotherapy through cellular senescence and cytoprotective autophagy will highlight the importance of targeting non-apoptotic survival pathways to enhance chemotherapeutic efficacy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2 retracted
Items 201–226 of 226
Platinum-based chemotherapy in triple-negative breast cancer: A meta-analysis
LIU, M., Mo, Q., Wei, C., Qin, Q., Huang, Z., & HE, J. (2012) · Oncology Letters · doi:10.3892/ol.2012.1093 · Cited by 59
Khoshnoud, M. R., Löfdahl, B., Fohlin, H., Fornander, T., Stål, O., Skoog, L. K., Bergh, J. C. S., & Nordenskjöld, B. A. (2010) · Breast Cancer Research and Treatment · doi:10.1007/s10549-010-1202-7 · Cited by 59
GRB7 is required for triple-negative breast cancer cell invasion and survival
Giricz, O., Calvo, V., Pero, S. C., Krag, D. N., Sparano, J. A., & Kenny, P. A. (2011) · Breast Cancer Research and Treatment · doi:10.1007/s10549-011-1822-6 · Cited by 58
Havre, P. A., O’Reilly, S., McCormick, J. J., & Brash, D. E. (2002) · PubMed · Cited by 53
Cellular senescence induced by aberrant MAD2 levels impacts on paclitaxel responsiveness in vitro
Prencipe, M., Fitzpatrick, P., Gorman, S., Mosetto, M., Klinger, R., Furlong, F. M., Harrison, M. J., O’Connor, D. P., Roninson, I. B., O’Sullivan, J. M., et al. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6605419 · Cited by 53
Self-citationZhou, F.-F., Yan, M., Guo, G., Wang, F., Qiu, H., Zheng, F.-M., Zhang, Y., Liu, Q., Zhu, X., & Xia, L.-P. (2010) · Medical Oncology · doi:10.1007/s12032-010-9630-0 · Cited by 51
D’Agostini, F., Bagnasco, M., Giunciuglio, D., Albini, A., & Flora, S. D. (1998) · International Journal of Oncology · doi:10.3892/ijo.13.2.217 · Cited by 51
Neumeister, V. M., Sullivan, C. A. W., Lindner, R. M., Lezon-Geyda, K., Li, J., Závada, J., Martel, M., Glazer, P. M., Tuck, D. P., Rimm, D. L., et al. (2012) · Breast Cancer Research and Treatment · doi:10.1007/s10549-012-2232-0 · Cited by 48
Autophagy in cancer: Having your cake and eating it
Hoare, M., Young, A. R. J., & Narita, M. (2011) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2011.09.004 · Cited by 47
Rugo, H. S., Roche, H. H., Thomas, E., Blackwell, K., Chung, H., Lerzo, G. L., Volles, L., Poulart, V., & Perez, E. A. (2009) · Cancer Research · doi:10.1158/0008-5472.sabcs-3057 · Cited by 46
Noscapine sensitizes chemoresistant ovarian cancer cells to cisplatin through inhibition of HIF-1α
Su, W., Huang, L., Ao, Q., Zhang, Q., Tian, X., Fang, Y., & Lu, Y. (2011) · Cancer Letters · doi:10.1016/j.canlet.2011.02.031 · Cited by 44
Salem, A. F., Howell, A., Sartini, M., Sotgia, F., & Lisanti, M. P. (2012) · Cell Cycle · doi:10.4161/cc.22316 · Cited by 44
Senescence and pre-malignancy: How do tumors progress?
Saab, R. H. (2011) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2011.09.013 · Cited by 42
Management Options in Triple-Negative Breast Cancer
Minami, C. A., Chung, D. U., & Chang, H. R. (2011) · Breast Cancer Basic and Clinical Research · doi:10.4137/bcbcr.s6562 · Cited by 41
Haakensen, V. D., Lingjærde, O. C., Lüders, T., Riis, M. L. H., Prat, A., Troester, M. A., Holmen, M. M., Frantzen, J. O., Romundstad, L., Navjord, D., et al. (2011) · BMC Medical Genomics · doi:10.1186/1755-8794-4-77 · Cited by 40
The Role of Autophagy in Clinical Practice
Swampillai, A., Salomoni, P., & Short, S. C. (2011) · Clinical Oncology · doi:10.1016/j.clon.2011.09.010 · Cited by 36
Hypoxia decreased chemosensitivity of breast cancer cell line MCF-7 to paclitaxel through cyclin B1
Dong, X. L., Xu, P., Miao, C., Fu, Z.-Y., Li, Q. P., Tang, P., & Wang, T. (2011) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2011.11.016 · Cited by 34
Uehara, N., Kanematsu, S., Miki, H., Yoshizawa, K., & Tsubura, A. (2011) · Cancer Letters · doi:10.1016/j.canlet.2011.07.032 · Cited by 33
Novel monoclonal antibodies identify antigenic determinants unique to cellular senescence
Porter, M. B., Pereira‐Smith, O. M., & Smith, J. R. (1990) · Journal of Cellular Physiology · doi:10.1002/jcp.1041420228 · Cited by 30
The significance of the senescence pathway in breast cancer progression
Pare, R. B., Yang, T., Shin, J., & Lee, C. S. (2013) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2012-201081 · Cited by 30
Giaccone, G., & Pinedo, H. M. (1996) · PubMed · Cited by 24
Bhattacharyya, G. S., Basu, S., Agarwal, V., Malhotra, H., Pareekh, P., Babu, K. G., & Aggarwala, D. (2009) · European Journal of Cancer Supplements · doi:10.1016/s1359-6349(09)72076-2 · Cited by 23
Koo, J. S., & Jung, W. (2010) · Pathobiology · doi:10.1159/000320936 · Cited by 21
Signaling for Integrin α5/β1 Expression in Helicobacter pylori–Infected Gastric Epithelial AGS Cells
Cho, S. O., Kim, K. H., Yoon, J., et al. (2006) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1378.032 · Cited by 20
Cellular Senescence: Many Roads, One Final Destination
Saab, R. H. (2010) · The Scientific World JOURNAL · doi:10.1100/tsw.2010.68 · Cited by 16
Tan, A. R., Gibbon, D. G., Stein, M. N., Moss, R. A., Karantza, V., Lin, H. M., Gounder, M. M., Chen, A. P., Egorin, M. J., & DiPaola, R. S. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.15_suppl.3000 · Cited by 13
Cited by
Deepak, K. G. K., Vempati, R., Nagaraju, G. P., Dasari, V. R., S., N., Rao, D. N., & Malla, R. R. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.104683 · Cited by 614
Breast Cancer: Current Perspectives on the Disease Status
Fahad Ullah, M. (2019) · Advances in Experimental Medicine and Biology · doi:10.1007/978-3-030-20301-6_4 · Cited by 598
Triple Negative Breast Cancer Treatment Options and Limitations: Future Outlook
Obidiro, O., Battogtokh, G., & Akala, E. O. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15071796 · Cited by 511
Cazet, A. S., Hui, M. N., Elsworth, B. L., Wu, S. Z., Roden, D., Chan, C.-L., Skhinas, J. N., Collot, R., Yang, J., Harvey, K., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-05220-6 · Cited by 437
Fleury, H., Malaquin, N., Tu, V., Gilbert, S., Martinez, A., Olivier, M.-A., Sauriol, S. A., Communal, L., Leclerc-Desaulniers, K., Carmona, E., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-10460-1 · Cited by 228
Metadata
- Authors
- O’Reilly, E. A., Gubbins, L., Sharma, S., Tully, R., Guang, M. H. Z., Weiner-Gorzel, K., McCaffrey, J., Harrison, M., Furlong, F., Kell, M., & McCann, A.
- Venue
- BBA Clinical
- Publisher
- Elsevier BV
- Published
- 2015-06
- Volume
- 3
- Pages
- 257-275
- ISSN
- 2214-6474 (ISSN-L)
- OpenAlex
- W2156871941
- Cited by
- 377
- References
- 226
- FWCI
- 10.60
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.